At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia
In Brief
A Phase 2 clinical trial evaluating Durvalumab, Lenalidomide, and 3 other interventions for Lymphoma and Leukemia, Lymphocytic, Chronic, B-Cell. Completed, enrolled 106 participants across 66 sites in 7 countries.
Detailed Summary
This study is designed to determine the recommended phase 2 dose (RP2D), and the safety, and efficacy of durvalumab as monotherapy and when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab at the RP2D in adults with lymphoma or chronic lymphocytic leukemia (CLL).
Study Details
Timeline
Interventions
Administered as an IV infusion (250 mL) over approximately 1 hour in duration
Administered orally
Administered by intravenous infusion
Administered orally
Administered as a 30-minute intravenous infusion